FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207934479> ?p ?o ?g. }

• W3207934479 abstract "<h3>Introduction/Background*</h3> Cervical cancer is the fourth most common cause of cancer-related deaths in women worldwide. With screening for precancerous lesions and vaccination for preventive human papillomavirus (HPV), a survival improvement has been observed in these patients in developed countries. In recent years, immunotherapy has represented a breakthrough in oncology and immune-checkpoint inhibitors have shown antitumor activity in a variety of tumor types. Here, we present the first systematic review discussing the efficacy and clinical usefulness of pembrolizumab, an anti-PD-1 checkpoint inhibitor, in the treatment of advanced cervical cancer. <h3>Methodology</h3> A systematic literature search was performed on March 2021 according to PRISMA statement using multiple databases and selective medical search terms (MeSH) such as ’uterine cervical neoplasms’ AND ’Pembrolizumab’. After a detailed primary and secondary screening conducted by two members of 188 studies, total 7 studies were included (<i>Chung et al. 2019, Frenel et al. 2017, </i><i>Choi, M et al. 2020, H Chung et al. 2018, </i><i>SH Kim al. 2019, J Zhu et al.2019, </i><i>K. Miller et al. 2020</i>). <h3>Result(s)*</h3> A total of 411 patients, mean age of 48 years (21-76) with advanced cervical cancer who had received a median range of 1-7 previous lines of therapies, were included. In all studies, pembrolizumab monotherapy reported a cumulative median duration of follow up of 10.5 months (0-32.2), overall response rate (ORR) of 15% (n=47/313), and complete response of 3.76% (n=14/372). Very Good partial response was not reported in any study. A calculated pooled partial response, stable disease, and progressive disease were reported respectively [9.7%(n=40/411) vs. 19.3% (n=67/346) vs. 41%(n=145/348)]. Six-month overall survival as presented in 3 studies was 67%(n=160/239). The progression free survival and survival data is premature at this stage and requires further elaboration in phase II/III clinical trials. <h3>Conclusion*</h3> Pembrolizumab (KEYTRUDA) monotherapy demonstrated durable antitumor activity in patients with advanced cervical cancer. However, further studies using combinations with other treatment options including chemotherapy, radiotherapy and other immunotherapeutic agents should be explored for the efficacy and survival outcomes." @default.
• W3207934479 created "2021-10-25" @default.
• W3207934479 creator A5004349926 @default.
• W3207934479 creator A5023322506 @default.
• W3207934479 creator A5025126436 @default.
• W3207934479 creator A5025510150 @default.
• W3207934479 creator A5028159870 @default.
• W3207934479 creator A5035469744 @default.
• W3207934479 creator A5040010155 @default.
• W3207934479 creator A5042911120 @default.
• W3207934479 creator A5043026057 @default.
• W3207934479 creator A5047580018 @default.
• W3207934479 creator A5058675387 @default.
• W3207934479 creator A5062276126 @default.
• W3207934479 creator A5062279447 @default.
• W3207934479 creator A5081328520 @default.
• W3207934479 creator A5081908748 @default.
• W3207934479 creator A5087005055 @default.
• W3207934479 date "2021-10-01" @default.
• W3207934479 modified "2023-09-23" @default.
• W3207934479 title "567 Efficacy of checkpoint inhibitor immunotherapy drug pembrolizumab (KEYTRUDA) for treatment of advanced cervical cancer" @default.
• W3207934479 doi "https://doi.org/10.1136/ijgc-2021-esgo.43" @default.
• W3207934479 hasPublicationYear "2021" @default.
• W3207934479 type Work @default.
• W3207934479 sameAs 3207934479 @default.
• W3207934479 citedByCount "0" @default.
• W3207934479 crossrefType "proceedings-article" @default.
• W3207934479 hasAuthorship W3207934479A5004349926 @default.
• W3207934479 hasAuthorship W3207934479A5023322506 @default.
• W3207934479 hasAuthorship W3207934479A5025126436 @default.
• W3207934479 hasAuthorship W3207934479A5025510150 @default.
• W3207934479 hasAuthorship W3207934479A5028159870 @default.
• W3207934479 hasAuthorship W3207934479A5035469744 @default.
• W3207934479 hasAuthorship W3207934479A5040010155 @default.
• W3207934479 hasAuthorship W3207934479A5042911120 @default.
• W3207934479 hasAuthorship W3207934479A5043026057 @default.
• W3207934479 hasAuthorship W3207934479A5047580018 @default.
• W3207934479 hasAuthorship W3207934479A5058675387 @default.
• W3207934479 hasAuthorship W3207934479A5062276126 @default.
• W3207934479 hasAuthorship W3207934479A5062279447 @default.
• W3207934479 hasAuthorship W3207934479A5081328520 @default.
• W3207934479 hasAuthorship W3207934479A5081908748 @default.
• W3207934479 hasAuthorship W3207934479A5087005055 @default.
• W3207934479 hasBestOaLocation W32079344791 @default.
• W3207934479 hasConcept C121608353 @default.
• W3207934479 hasConcept C126322002 @default.
• W3207934479 hasConcept C143998085 @default.
• W3207934479 hasConcept C2777701055 @default.
• W3207934479 hasConcept C2778220009 @default.
• W3207934479 hasConcept C2780030458 @default.
• W3207934479 hasConcept C2780057760 @default.
• W3207934479 hasConcept C2780674031 @default.
• W3207934479 hasConcept C71924100 @default.
• W3207934479 hasConceptScore W3207934479C121608353 @default.
• W3207934479 hasConceptScore W3207934479C126322002 @default.
• W3207934479 hasConceptScore W3207934479C143998085 @default.
• W3207934479 hasConceptScore W3207934479C2777701055 @default.
• W3207934479 hasConceptScore W3207934479C2778220009 @default.
• W3207934479 hasConceptScore W3207934479C2780030458 @default.
• W3207934479 hasConceptScore W3207934479C2780057760 @default.
• W3207934479 hasConceptScore W3207934479C2780674031 @default.
• W3207934479 hasConceptScore W3207934479C71924100 @default.
• W3207934479 hasLocation W32079344791 @default.
• W3207934479 hasOpenAccess W3207934479 @default.
• W3207934479 hasPrimaryLocation W32079344791 @default.
• W3207934479 hasRelatedWork W10084525 @default.
• W3207934479 hasRelatedWork W10395743 @default.
• W3207934479 hasRelatedWork W10741706 @default.
• W3207934479 hasRelatedWork W11223332 @default.
• W3207934479 hasRelatedWork W19832868 @default.
• W3207934479 hasRelatedWork W20714511 @default.
• W3207934479 hasRelatedWork W3521414 @default.
• W3207934479 hasRelatedWork W5413298 @default.
• W3207934479 hasRelatedWork W8234051 @default.
• W3207934479 hasRelatedWork W18642656 @default.
• W3207934479 isParatext "false" @default.
• W3207934479 isRetracted "false" @default.
• W3207934479 magId "3207934479" @default.
• W3207934479 workType "article" @default.